Deborah Ann Miller

CLO Deborah Ann Miller sold 5,500 shares at $107.84 avg for $593.1K via scheduled 10b5-1 plan on 2026-05-28

Deborah Ann Miller, Chief Legal Officer, executed 4 separate sales totaling 5,500 shares for $593,100.52 pursuant to a 10b5-1 trading plan adopted on 2024-11-18, reducing her non-derivative holdings from 65,134 shares to 59,634 shares. The stock currently trades at $93.01, down 17.7% from its 52-week high of $113.02, and Miller maintains derivative holdings of 72,608 stock options, preserving meaningful upside exposure. Nuvalent is unprofitable with net income of $-109,279,000.00 over its most recent full fiscal year, and her prior transactions at this ticker (5 prior sells) showed positive returns in both 30-day and 90-day windows following execution. As a scheduled transaction under a pre-arranged plan rather than a discretionary trade, this sale reflects a formulaic execution independent of current market conditions.

Chief Legal Officer of unprofitable Nuvalent executes mixed transaction: small stock purchase offset by substantial sale near current levels

Deborah Ann Miller, Chief Legal Officer at Nuvalent, executed a complex three-part transaction on the same day: a modest stock purchase of approximately 5,500 shares paired with two separate sales totaling roughly 5,500 shares for a combined value exceeding $545,000. The timing is notable—the sales occurred at prices slightly above the current trading level, suggesting Miller locked in value near recent market expectations rather than capitulating during a deep decline. However, the company remains deeply unprofitable with significant operating losses, which typically constrains executive appetite for equity accumulation. The overall pattern reads less as insider conviction and more as routine rebalancing by an officer managing tax obligations or diversification needs, especially given that the buy and sell volumes nearly offset each other on the same date.

Chief Legal Officer Deborah Miller sold 5,500 NUVL shares for $542,991.35 at blended average $98.73; holds 59,634 post-trade as stock down -13.6% from 52-week high.

Chief Legal Officer Deborah Ann Miller executed three separate sales on 2026-03-26 totaling 5,500 shares for $542,991.35 at blended average $98.73, representing an 8.4% reduction in her holdings to 59,634 shares. The transaction occurred as NUVL trades at $96.72, down 5.1% over 30 days and 13.6% from its 52-week high of $111.99, while the company reported a net loss of $122.4M over its most recent full fiscal year. Her prior four trades at NUVL over the past two months have all experienced negative 30-day returns (-5.8%, -7.0%, -6.5%, -8.8%, -8.5%), establishing a pattern of selling into sustained price declines at this ticker.

CLO Deborah Ann Miller sold 5,500 shares at blended avg $103.05 (totaling $566.8K) on 2026-02-26; stock now at $101.29, down 1.6% in 30 days.

Miller, Chief Legal Officer, executed 3 separate sales totaling 5,500 shares for $566,787.54, reducing her holdings by 8.4% from 65,134 shares to 59,634 shares post-transaction. The transaction occurred at an average price of $103.05, while the current price is $101.29, placing the stock -1.6% over 30 days and -3.5% over 90 days from transaction date. Her recent same-ticker history shows 5 prior sells at NUVL over late January 2026, with mixed near-term outcomes (ranging from +4.3% to -8.8% at 30 days), though no 90-day outcomes are yet measurable on those trades. The company reported a net loss of $-122,437,000.00 on a $317.0M market capitalization, indicating material financial distress that may provide context for ongoing insider activity.

CLO Miller sells 15,000 NUVL shares for $1,652,176 across 2 trades; retains 59.6K shares.

Deborah Ann Miller, Chief Legal Officer at Nuvalent, executed 2 separate sales totaling 15,000 shares (15.0K shares) for $1,652,176.00 ($1.7M) at an average of $110.15 per share on January 21-22, 2026. This represents a -20.1% reduction in her post-transaction holdings to 59,634 shares (59.6K shares). The company is currently unprofitable with net income of $-122,437,000.00 ($-122.4M) for its most recent full fiscal year, and the stock is -5.0% from its 52-week high of $111.99. The timing of this sale near the 52-week peak warrants attention, though the CLO retained substantial holdings, indicating incomplete divestment. With 5 prior NUVL-specific sales in early January 2026 outcomes not yet measurable at 90 days, a pattern of regular insider sales at this ticker has emerged, though this does not constitute a coordinated multi-executive event.

NUVL CLO Deborah Ann Miller sold 10,000 shares for $1.0M under pre-arranged 10b5-1 plan

Deborah Ann Miller, Chief Legal Officer of Nuvalent, Inc., executed 3 separate sales totaling 10,000 shares for $1,005,114.30 at a blended average price of $100.51 on 2026-01-02. This sale reduced her holdings from 59,086 shares to 49,086 shares, a net change of -16.9% vs pre-transaction holdings. The transaction was executed pursuant to a pre-arranged 10b5-1 trading plan adopted on 2024-11-18, meaning it was scheduled rather than discretionary. As a scheduled disposition under a pre-arranged plan, this activity reflects compliance with Rule 10b5-1 mechanics rather than a real-time market signal tied to current conditions or conviction levels.

CLO Deborah Ann Miller sold 24,200 shares at avg $105.50 for $2.6M under pre-arranged 10b5-1 plan

Deborah Ann Miller, Chief Legal Officer at Nuvalent, Inc., executed 3 separate sales totaling 24,200 shares for $2,552,998.98 on 2025-11-17 at prices ranging from $105.16 to $107.04, reducing her holdings by 33.0% from 73.3K to 49.1K shares. This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2024-11-18, meaning it was scheduled and not discretionary. The systematic reduction of her position represents a substantial liquidation of nearly one-third of her stake, reflecting a pre-planned divestment program rather than event-driven trading.

Chief Legal Officer Deborah Miller sold 21,800 shares of NUVL for $2,248,943.44 on 2025-10-30 under pre-arranged 10b5-1 plan

Deborah Ann Miller, Chief Legal Officer of Nuvalent Inc., executed 8 separate sales totaling 21,800 shares for $2,248,943.44 at prices ranging from $96.65 to $104.78 on 2025-10-30, reducing her holdings by 30.8% from 70,886 to 49,086 shares. This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2024-11-18, meaning the sales were scheduled in advance rather than discretionary. The substantial reduction in CLO holdings warrants tracking to understand whether this reflects a planned liquidity event or broader strategic shifts in executive positioning, though the scheduled nature precludes any inference about transaction timing.

Chief Legal Officer Deborah Ann Miller sells 28,000 shares ($2.5M) via scheduled 10b5-1 plan at NUVL

Miller sold 28,000 shares in four separate transactions on 2025-10-15 and 2025-10-16 at prices ranging from $89.98 to $92.50, totaling $2,540,289.73. This sale reduced her holdings by 36.3% from 77,086 shares to 49,086 shares. However, these sales are part of a pre-arranged 10b5-1 trading plan adopted on 2024-11-18, meaning the timing and structure were scheduled in advance rather than discretionary. The blended average price of $90.72 reflects execution across a narrow price band over two trading days. Investors should note that 10b5-1 transactions are legally structured to avoid insider-trading concerns and do not reflect real-time decision-making by the executive.

CLO Deborah Ann Miller sold 8,000 shares (19.4% of holdings) at $93.22–$102.00 on 2024-09-16 for $771.8K.

Miller executed 7 separate sales totaling 8,000 shares for $771,798.25 on a single day, reducing her position from 41,300 to 33,300 shares. The sales occurred at prices ranging from $93.22 to $102.00, with a blended average of $96.47, occurring as the stock trades near its 52-week high of $112.17 and has appreciated 37.1% over the past 30 days and 30.9% over 90 days. Her prior sales at NUVL (4 measurable outcomes from June and earlier August 2024) posted an 0 of 4 well-timed rate at the 90-day horizon, with average 90-day returns of +5.2% to +11.6%, meaning the stock rose after each prior sale. The company reported a net loss of $57.2M over its most recent full fiscal year and has a $321.2M market cap, indicating an unprofitable early-stage biotech profile typical of the sector.